Cobro Ventures

Cobro Ventures is a private investment firm specializing in early-stage investments in the biotechnology and technology sectors. The firm focuses on providing resources, expertise, and capital to create significant value during critical phases of innovation. Their team has a 25+ year track record as founders, operators, and investors in technology businesses, with multiple successful exits via IPO and M&A.

The firm's investment strategy emphasizes 'doing well by doing good,' a principle championed by their late co-founder Marc A. Cohen. Cobro Ventures seeks to have a big impact by betting on world-class scientific and technology experts and leveraging their experience with intellectual property and strategic business development. They have been involved in various projects, including biotech companies targeting protein degradation and activating the body's innate healing ability, as well as technology ventures in AI and image-guided therapy.

Cobro Ventures operates from multiple locations, including McLean, Virginia; New York, New York; and Las Vegas, Nevada. Their portfolio includes companies such as Inovio Pharmaceuticals, AI Proteins, and Regenacy Pharmaceuticals. The firm is led by Marc Cohen, Co-Founder and Chief Executive Officer, and Todd Kaloudis, Managing Director and General Partner. For general inquiries, they can be contacted via email at info@cobroventures.com or by phone at (202) 421-7994. Their office is located at 175 Chain Bridge Rd., McLean, VA 22101.